ArticleEuropean geriatric medicine2025
Intrinsic capacity in community-dwelling older adults and cancer survivors: a comparative study.
Article in European geriatric medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo compare intrinsic capacity (IC) between older cancer survivors and community-dwelling older adults, and to examine the association between cancer history and IC using the ICOPE framework.
methodsThis cross-sectional study included 64 older adult cancer survivors who completed chemotherapy at least 12 months (CSG) prior and 52 community-dwelling older adults without cancer (CG). IC was assessed across five domains (cognitive, psychological, sensory, locomotor, and vitality), each scored from 0 to 2 points, yielding a total IC score (0-10). Participants were classified as: preserved IC (9-10), decline (5-8), or significant loss (≤ 4). Group comparisons were performed using t-tests, and associations between cancer history and IC were analyzed with multiple linear regression adjusted for age, sex, and platinum-based chemotherapy.
resultsThe CG had a mean age of 69 years (range 60-91; 37 females, 71.2%), while the CSG had a mean age of 71.4 years (range 60-90; 43 females, 67.2%). CSG scored significantly lower in cognitive, psychological, sensory, and locomotor domains compared to controls (p < 0.05). No significant differences were observed in vitality. Among CG, 51.9% had preserved IC versus 21.9% of survivors, while 10.9% of survivors exhibited significant IC loss compared to none in the CG. Regression analysis showed that absence of cancer was significantly associated with higher IC (p < 0.001).
conclusionCSG exhibit marked declines in specific domains of IC compared to their peers, even 1 year after treatment. The proposed IC scoring system may help identify functional vulnerabilities and support tailored interventions in geriatric oncology.
Indexed as
Identifiers
41212503What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.